Article Text
PostScript
Idiopathic pulmonary fibrosis: is all-cause mortality a practical and realistic end-point for clinical trials?
Statistics from Altmetric.com
Dear Editor,
We read with interest the article by Wells et al1 in which the problematic selection of primary end-points for treatment studies in idiopathic pulmonary fibrosis (IPF) patients is addressed. In this document endorsed by respiratory physicians across Europe, the authors explore the implications of using all-cause mortality as a primary end-point in response to a recent statement by a working group on this topic.2 In a rather controversial statement by this working group, Raghu et al suggested that all-cause mortality and all-cause non-elective hospitalisation are the strongest and cleanest clinically meaningful end-points for use in Phase 3 clinical …